Acceleron Pharma (XLRN) Tops Q1 EPS by 40c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/9/2026

1. HUM
2. SPCX
3. ALHC
4. T
5. PEP
6. CVS
7. UNH
8. AXP
9. ZETA
10. DAL

Go back to Acceleron Pharma (XLRN) Tops Q1 EPS by 40c

Acceleron Pharma Reports First Quarter 2016 Financial and Operational Results

May 5, 2016 7:00 AM EDT

- Received $15 million milestone payment for Celgene's initiation of luspatercept Phase 3 clinical trial -

- Raised $140.3 million in net proceeds to advance wholly owned programs -

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Acceleron Pharma Inc. (NASDAQ: XLRN), a clinical stage biopharmaceutical company focused on the discovery and development of novel therapeutic candidates that engage the bodys ability to rebuild and repair its own cells and tissues, today provided a corporate update and reported financial results for the first quarter ended March 31, 2016.

In the first... More